Financial Data and Key Metrics Changes - Revenue for 2025 was $386.2 million, an increase of $132.7 million or 52% year-over-year, primarily driven by increased completion against two transport layer Tranche 2 contracts [21][22] - Gross margin percentage improved to 20%, up 7 percentage points year-on-year, due to a better mix of newer programs and a reduction in negative EAC adjustments [22] - Contribution margin in 2025 was 32%, an increase of 2 percentage points from 2024's 30%, with contribution margin dollars growing by $47 million to $122 million, a 63% increase [25][26] Business Line Data and Key Metrics Changes - The company launched 23 satellites in 2025, emerging as a leading provider for the Department of Defense's Proliferated Warfighter Space Architecture [6][8] - The introduction of the M-class platform in 2025 allows for payloads exceeding 8 kW, broadening the addressable market across national security, civil, and commercial sectors [10] - The acquisition of ATLAS Space Operations enhanced ground infrastructure, critical for supporting proliferated architectures [11] Market Data and Key Metrics Changes - The company reported having 33 satellites currently on orbit and expects to have a total of 140 satellites by the end of 2027 [66] - The identified pipeline for future contracts stands at $11 billion, indicating strong demand and growth potential in the market [72] Company Strategy and Development Direction - The company aims to disrupt the traditional space industry by transforming satellite manufacturing and operations into a fully industrialized model [5] - The strategy includes expanding market share through M&A, as evidenced by the acquisition of Orbion Space Technology to reduce supply chain risk and enhance production capabilities [15][16] - The focus on government contracts and the growing demand for space-based defense systems positions the company favorably for future growth [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet the evolving needs of the U.S. government and commercial customers, citing a deteriorating global threat environment as a driver for increased investment in space [17][20] - The company anticipates revenue for 2026 to be in the range of $545 million to $595 million, with over 70% expected from existing backlog [27] Other Important Information - The company completed its IPO on January 30, 2026, raising net proceeds of $582.6 million, significantly enhancing its liquidity [23][24] - The company has a flexible and efficient manufacturing process, allowing for low capital expenditures compared to industry standards [26] Q&A Session Summary Question: Can you elaborate on the acquisition of Orbion? - The acquisition of Orbion was anticipated in the S-1 filing and is expected to enhance the company's technology roadmap and production capabilities [30][31] Question: What is the expected revenue contribution from Orbion this year? - Specific revenue guidance for Orbion is not provided, but it is included in the consolidated guidance figure [33] Question: What are the prospects for new business opportunities? - The company has won two IDIQ contracts for classified customers and expects robust award activity in the second half of the year [39][41] Question: How does the company view the PWSA architecture? - Management believes the PWSA architecture is critical for national defense and is evolving to ensure better coordination among various systems [50] Question: What is the current build rate and production capacity? - The company has invested heavily in production capacity, with the ability to produce up to 1,000 satellites a year, ensuring it can meet future demand [63][64]

Financial Data and Key Metrics Changes - Net revenue for Q4 2025 was $25.1 million, a decrease from $26.2 million in Q4 2024, primarily due to a decrease in deferred revenues recognized during 2025 of $3.5 million, partially offset by increased sales from the ARK franchise and Bellwright [14][15] - Full year net revenues for 2025 were $81.2 million, down from $84.5 million in 2024, mainly due to a $15.5 million decrease in deferred revenue recognition related to the ARK franchise [15][16] - Net loss for Q4 2025 was $900,000, compared to a net income of $1.1 million in Q4 2024, attributed to a decrease in gross profit and an increase in operating expenses [16][17] - Full year net loss for 2025 was $27.2 million, compared to a net income of $1.8 million in 2024, driven by a non-cash tax expense and increased operating expenses [16][17] - Bookings for Q4 2025 increased to $20.8 million from $17 million in Q4 2024, while full year bookings rose 16.2% to $87.8 million from $75.7 million in 2024 [19][20] Business Line Data and Key Metrics Changes - The ARK franchise saw a significant increase in sales, contributing an additional $1.3 million in Q4 2025, while Bellwright also contributed $1.2 million [14] - Total units sold for the year increased by 32.7% to 6.3 million, driven by a 1.7 million unit increase in the ARK franchise [18] Market Data and Key Metrics Changes - ARK Mobile surpassed 10 million cumulative downloads, maintaining an average daily active user (DAU) of approximately 130,000 [7] - ASA achieved approximately 692,000 units sold in Q4 2025, with an average DAU of over 91,000 and a peak DAU of over 147,000 [6] Company Strategy and Development Direction - The company is focused on expanding the ARK franchise with a multi-year content roadmap, including four major DLCs planned for 2026 and additional titles in 2027 [8][12] - The company aims to enhance its internal development capabilities, having increased from one to four development studios, with three studios working on in-house projects [36][64] - The company is also investing in indie titles and interactive films, with plans to release numerous short dramas and new gaming projects [22][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong content pipeline and the potential for significant revenue from upcoming titles [13][23] - The company anticipates a 20%-30% revenue growth compared to the previous year, driven by various projects and game releases [68] Other Important Information - The company has minted its first official USDO stablecoin and is exploring partnership opportunities related to this initiative [23] - The development of the game "For The Stars" is progressing well, with external testing expected to begin by the end of the year [44] Q&A Session Summary Question: What is the ending deferred revenue balance in the quarter? - The deferred revenue balance is around $30 million [26] Question: Is the technology gap still persistent? - The CEO stated that the company has upgraded to Unreal Engine 5.7, eliminating any technical gaps in game development [34] Question: Do you have a launch window for your triple-A games? - The CEO mentioned that the internal development system has been fully transformed, and they are on track for successful launches [36] Question: What are the expected revenues from the upcoming IPs? - The CEO expects at least $60 million-$80 million in revenues from each of the three major IPs being developed [57] Question: What is the revenue growth projection for 2026? - The company anticipates significant revenue growth from various projects, including Bellwright and new titles, with expectations of doubling revenues from Bellwright after its console release [58][64]

Financial Data and Key Metrics Changes - In 2025, net sales were approximately $162 million, a decline from $188.9 million in 2024, primarily due to store closures [20][21] - Gross margin improved by 370 basis points to 26.8% for 2025, compared to 23.1% in 2024 [22] - GAAP net loss decreased to $24 million for 2025, or -$0.40 per share, a $25.5 million improvement from a net loss of $49.5 million in 2024 [22] - Adjusted EBITDA improved by $8.5 million year-over-year, from a loss of $14.5 million in 2024 to a loss of $6 million in 2025 [8][22] Business Line Data and Key Metrics Changes - Proprietary brand sales accounted for 32.8% of cultivation and gardening revenue in 2025, up from 24.2% in 2024 [20] - In Q4 2025, proprietary brand sales represented 35.8% of cultivation and gardening revenue, up from 30.4% in the prior year [16] - The storage solutions segment reported net sales of $5.7 million in Q4 2025, an increase from $4.5 million in Q4 2024 [16] Market Data and Key Metrics Changes - The company consolidated 8 retail stores in 2025, reducing its retail footprint to 23 locations as of December 31 [5] - Same-store sales remained stable, indicating business stabilization despite fewer retail locations [6] Company Strategy and Development Direction - The company aims to reach approximately break-even adjusted EBITDA for the full year 2026, focusing on revenue quality rather than volume [5][24] - Plans to increase proprietary brand sales to 40% of cultivation and gardening revenue by year-end 2026 [9][24] - The company is shifting towards a national controlled environment agriculture supplier, focusing on larger specialty agricultural markets [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term strategy and the potential for sustainable growth in the controlled environment agricultural industry [15] - The restructuring efforts in 2025 have laid a strong foundation for future profitability, with expectations of continued margin improvement [27][29] Other Important Information - The company announced a share repurchase program for up to $10 million of its outstanding common stock, reflecting confidence in its long-term strategy [14][23] - The company ended 2025 with $46.1 million in cash and no debt, maintaining a strong balance sheet [23] Q&A Session Summary Question: Share repurchase program considerations - Management indicated that the decision to initiate a share repurchase program was based on the current undervaluation of the stock and the lack of suitable acquisition opportunities [31][32] Question: Sales channels for proprietary brands - Currently, about 80% of proprietary brand sales are through GrowGen's own channels, with plans to diversify towards third-party channels [34][35] Question: Outlook for storage solutions segment - Management noted that the storage solutions segment is experiencing growth and is being consolidated into one location to enhance efficiency [38][39] Question: Future of retail store base - The company is transitioning to a B2B model, with plans to reduce the number of retail locations further, focusing on distribution centers instead [56][58] Question: Operating expenses outlook - Management expects continued reductions in operating expenses in 2026, driven by the impact of store closures and ongoing cost improvement initiatives [59][60]

Financial Data and Key Metrics Changes - For Q4 2025, gross revenue was EUR 6.3 million before revenue deferrals of EUR 700,000, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [14] - Full year 2025 gross revenue was EUR 11 million before EUR 1 million of revenue deferrals, resulting in net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [15] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [14][15] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024, while the full year operating loss increased to EUR 83.5 million from EUR 58.8 million in 2024 [15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million in revenue generated from the first full quarter of launch [14][5] - 145 surgeons were trained in 125 high-volume hypoglossal nerve stimulation accounts, with 57 receiving positive Value Analysis Committee approval [5][7] Market Data and Key Metrics Changes - The company secured reimbursement for Genio across both Medicare and commercial payers, with Medicare representing 10% of the business and commercial payers approximately 90% [9][10] - The introduction of new C-codes for hypoglossal nerve stimulation by CMS is expected to facilitate billing and reimbursement processes [10] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - Plans for 2026 include expanding internal manufacturing to strengthen competitive position and improve gross margins [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, with expectations for U.S. net revenue to grow 25% sequentially in Q1 and Q2 2026 [16] - The company anticipates a strong financial profile as it gains market share in the U.S. [17] Other Important Information - The DREAM pivotal study published in the Journal of Clinical Sleep Medicine demonstrated Genio's clinical efficacy, differentiating it from competitors [6] - The company closed 2025 with a global gross revenue of EUR 11 million, driven by strong Q4 U.S. launch momentum [6] Q&A Session Summary Question: Update on VAC submissions and account activations - Management confirmed 120 VAC submissions with 57 approvals, expecting more approvals in Q1 2026 [21][22] Question: Timing for ACCESS study data and PMA supplement submission - The 12-month data will be available by the end of June 2026, with submission planned for Q1 2027 [24] Question: Cash burn rate and guidance for 2026 - Cash burn is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases [29] Question: Competitor's coding strategy and implant numbers - Management indicated plans to pursue dedicated coding for Genio by 2028, while not disclosing specific implant numbers [31][33] Question: Key drivers for Genio adoption among physicians - Surgeons are attracted to Genio's unique features, including bilateral stimulation and a single incision procedure [51]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 12% to a record $6.6 million, with full-year revenue increasing 13% to $22.7 million, marking another company record [6][23] - Gross margin for Q4 2025 increased to 91.4% from 91.1% in Q4 2024, reflecting the strength of the software-driven SaaS model [6][25] - The company achieved annual operating profitability for the first time since going public, with net income of $1.3 million and EPS of $0.06 for the year [7][23] - Adjusted EBITDA for Q4 2025 was a record $1.9 million, with full-year adjusted EBITDA reaching $2.6 million, nearly five times the previous year [7][23] Business Line Data and Key Metrics Changes - SaaS revenue for Q4 2025 grew 12% to $6.62 million, representing over 99% of total revenue for the quarter [25] - The average price per transaction increased by 25% in Q4 2025 compared to the previous year, indicating pricing power for the company's unique product [18] Market Data and Key Metrics Changes - The banking and lending sector showed significant growth, with year-over-year revenue growth nearly doubling, while retail was down 1% year-over-year [39] - The automotive sector experienced a 125% year-over-year revenue growth, with significant opportunities for expansion through channel partners [71] Company Strategy and Development Direction - The company aims to build a durable, differentiated, high-margin business by expanding with existing customers and onboarding new ones while maintaining disciplined execution [21] - Continued investment in customer success and deepening presence in key verticals, particularly financial services and banking, is a strategic priority [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in various verticals, particularly in banking and automotive, despite current economic challenges [17][18] - The company is well-positioned to benefit from a potential decrease in interest rates, which could act as a tailwind for growth [54] Other Important Information - The company has a strong cash position, ending the year with $9.6 million in cash and cash equivalents, reflecting strong cash generation from operations [35] - The decline in software capitalization from over $2 million in 2024 to just $213,000 in 2025 indicates a cleaner financial profile moving forward [36] Q&A Session Summary Question: What was the revenue breakdown for the banking and retail channels in Q4? - Management noted that banking and lending revenue continues to grow significantly, while retail saw a seasonal increase but was down year-over-year [39][41] Question: How does the pipeline look for new customers in 2026? - The pipeline appears strong, driven by interest in the new desktop solution and partnerships, particularly with Alloy [42][43] Question: What is the status of the relationship with Ping Identity? - Management acknowledged the need for improvement in leveraging the partnership with Ping Identity to facilitate growth [47] Question: Can you provide growth expectations for 2026? - While the company does not provide formal guidance, management expressed confidence in built-in growth from existing clients and new implementations [63] Question: What metrics can be shared regarding the automotive sector? - Automotive revenue grew 125% year-over-year, with significant opportunities for further penetration through channel partners [71]

Financial Data and Key Metrics Changes - For fiscal 2025, the company achieved net sales of $1 billion and adjusted EBITDA of $63.6 million, reaching the top end of its guidance [4][22] - In Q4, net sales were $236.2 million, down from $275.6 million in the prior year, with a comparable sales decline of 10% [23] - Gross profit for Q4 was $70.9 million, with a gross margin of 30%, compared to 33.6% in the prior year [23] - SG&A expenses decreased by $11.4 million to $62.4 million, representing 26.4% of net sales [23][24] - The net loss for Q4 was $8.1 million, or $0.08 per share, compared to a net loss of $3 million, or $0.03 per share, in the previous year [24] Business Line Data and Key Metrics Changes - The company saw strength in dresses, with growth for four consecutive quarters, and a turnaround in knit tops in the latter half of Q4 [6][7] - Sub-brands generated over $70 million in sales in 2025, with projected growth of approximately 60% in 2026 to around $110 million [11] - The footwear category was successfully reintroduced, with sold-out limited assortments, and is expected to contribute positively in the back half of 2026 [7][15] Market Data and Key Metrics Changes - The company closed 151 stores in fiscal 2025, with an additional 11 closures in Q1 2026, optimizing its store footprint [8][25] - Customer retention rates from closed locations have performed consistently with historical levels, validating the network strategy [25][26] - The company entered 2026 with a balanced inventory position of $136.5 million, down 8% [25] Company Strategy and Development Direction - The primary focus for 2026 is accelerating customer file growth through retention, reactivation, and acquisition [4][7] - The company aims to optimize its channel, product, and pricing platforms, with a disciplined approach to product development [20][19] - The opening price point strategy now represents approximately 30% of total assortment and is expected to grow to nearly 40% [16][20] Management Comments on Operating Environment and Future Outlook - Management acknowledged economic pressures affecting customer spending and emphasized the importance of accessible pricing [36][51] - The company expects to face headwinds in the first half of 2026 but anticipates a positive impact in the second half, particularly from the footwear category [15][47] - The outlook for fiscal 2026 includes expected net sales of $940 million to $960 million and adjusted EBIT of $65 million to $75 million [27] Other Important Information - The company has completed a substantial two-year transformation, optimizing its channel, product, and pricing platforms [20] - The marketing investment decreased by $1.9 million to $13.5 million, reflecting a more disciplined approach [24] - The company has over 7 million lapsed customers reachable through owned marketing channels, presenting a significant opportunity for reactivation [19][20] Q&A Session Summary Question: Insights on sub-brands performance and growth expectations - Management expressed satisfaction with sub-brands, highlighting strong performers and adjusting growth expectations to mid-teens for 2026 [31][32] Question: Reasons for customer lapses and reactivation strategies - Management noted economic pressures as a primary reason for lapses and emphasized targeted segmentation and personalized messaging for reactivation [36][37] Question: Sales cadence during the holiday season and tariff impacts - Management reported improvement in January sales and acknowledged tariff pressures affecting margins, particularly in footwear [42][44] Question: Marketing plans for pricing and loyalty program changes - Management discussed a shift towards less reliance on Torrid Cash and more focus on opening price points and targeted promotions to drive frequency [50][51] Question: Future pricing and promotional strategies - Management indicated a more personalized approach to promotions and pricing, leveraging opening price points and sub-brands to engage customers [67][68] Question: Consumer behavior changes and expectations regarding refunds - Management observed consistent consumer behavior but noted economic pressures influencing spending; no outsized expectations related to tax refunds were embedded in guidance [75][77]

Financial Data and Key Metrics Changes - Relmada closed 2025 with a cash balance of $93 million, an increase from approximately $45 million at December 31, 2024, due to net proceeds from a $160 million private financing [19][20] - Research and development expenses for Q4 2025 totaled $8.1 million, a decrease from $11 million in Q4 2024, primarily due to reduced study costs [21] - General and administrative expenses increased to $12.3 million in Q4 2025 from $8.1 million in Q4 2024, driven by higher compensation costs [22] - The net loss for Q4 2025 was $19.9 million, or $0.27 per share, compared to a net loss of $18.7 million, or $0.62 per share, in Q4 2024 [23] Business Line Data and Key Metrics Changes - The NDV-01 program reported a 12-month complete response rate of 76% in high-risk NMIBC patients, with an 80% response rate in the BCG unresponsive population [11][12] - The planned phase III RESCUE program will evaluate NDV-01 in both second-line BCG unresponsive disease and as adjuvant therapy for intermediate-risk bladder cancer [14][15] Market Data and Key Metrics Changes - The U.S. market for intermediate-risk bladder cancer is estimated to have about 75,000-80,000 patients, with only 35% currently receiving adjuvant therapy [53] - The second-line treatment population for BCG unresponsive patients is estimated at about 5,000 patients per year in the U.S. [15] Company Strategy and Development Direction - The company aims to initiate the phase III RESCUE program for NDV-01 in mid-2026, focusing on two independent registrational pathways [6][14] - The strategy includes addressing unmet needs in bladder cancer treatment with a unique sustained-release formulation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical programs and long-term prospects for Relmada, highlighting the importance of execution in the upcoming RESCUE program [24] - The company anticipates 2026 to be another significant year for value creation, with the initiation of key clinical trials [8] Other Important Information - The company has strengthened its development team with the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Oncology [7] - A successful $160 million private financing was completed, providing capital through 2029 [8] Q&A Session Summary Question: Will additional data from the phase II study be presented? - Management confirmed that updated 12-month data will be presented at the AUA and plans to share data every three months as the RESCUE trial progresses [29][30] Question: How will the company ensure that second-line patients are accurately categorized? - The company will limit prior therapy lines to two and will monitor patient characteristics closely to ensure accurate categorization [31] Question: What is the expected enrollment cadence across the studies? - Management indicated that the unique in-office profile of NDV-01 could serve as a recruitment advantage, and they expect rapid enrollment [34] Question: What is the FDA's requirement for follow-up duration prior to submitting the NDA? - The FDA has not stipulated a minimum follow-up duration but is interested in the totality of the data, including response and durability [36] Question: How does the company expect to compare against competitors in terms of CR rates? - Management indicated that they are targeting a two-year RFS of 75% and believe they can exceed this based on their data [42] Question: How does the company plan to build the market for intermediate-risk patients? - Management noted that the market is currently underserved, with only 35% receiving adjuvant therapy, and expects this number to grow as data from their studies becomes available [54]

Financial Data and Key Metrics Changes - In Q3, revenues were $329.1 million, down from $335.4 million in the prior year period, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break even compared to $6 million in the prior year [20] - Net loss was $3.5 million compared to a net loss of $1.3 million in the prior year period, with adjusted loss per diluted share increasing to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair [22] - Trade Publishing revenues were $69.7 million, down 10% from $77.4 million in the prior year, reflecting timing of major releases [23] - Education segment revenues were $56.1 million, down 2% from $57.2 million, but adjusted operating loss improved to $5.2 million from $6.9 million [25] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million a year ago, with a decline attributed to publication timing [26] - Demand for English language learning materials continues to expand globally, representing a long-term opportunity [18] Company Strategy and Development Direction - The company completed sale leaseback transactions generating over $400 million in net proceeds, optimizing the balance sheet and enhancing shareholder value [4][19] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5][29] - The company aims to return to growth in the education segment by fiscal 2027, focusing on improving product alignment with district needs [16] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million-$156 million, including a partial year impact from sale-leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving flat revenue for the full fiscal year, with expectations of 2% growth in Q4 [36][38] Other Important Information - The company established long-term net leverage targets of 2x-2.5x Adjusted EBITDA, balancing balance sheet strength with investment opportunities [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth in Q4 - Management highlighted Book Fairs as a major factor for revenue growth, with positive initial indications [37][38] Question: Sales pipeline for education solutions - Management noted improvements in the sales pipeline, particularly for summer reading and supplemental materials [42] Question: Adjusted EBITDA guidance and factors influencing it - Management indicated confidence in Q4 profitability due to cost mitigation actions and expected performance in the Entertainment segment [46][48] Question: Performance of the Book Fairs business - Management reported an increase in the number of fairs and revenue per fair, with fewer cancellations compared to the prior year [56] Question: Adjustments to revenue guidance - Management clarified that the adjustment was related to dynamics in the Trade business and not solely the Education segment [60][68]

Financial Data and Key Metrics Changes - In 2025, net sales were approximately $162 million, reflecting a year-over-year decline primarily due to store closures [5][20] - Gross margin improved by 370 basis points to 26.8% for the full year 2025, despite total revenue decline [4][22] - Adjusted EBITDA improved by $8.5 million year-over-year, moving from a loss of $14.5 million to a loss of $6 million [8][22] - GAAP net loss decreased to $24 million for the full year 2025, a $25.5 million improvement compared to a net loss of $49.5 million in 2024 [22] Business Line Data and Key Metrics Changes - Proprietary brand sales penetration increased to 32.8% of cultivation and gardening revenue for the full year 2025, up from 24.2% in 2024 [7][20] - In Q4 2025, proprietary brand sales represented 35.8% of cultivation and gardening revenue, up from 30.4% in the prior year [16] - The storage solutions segment reported net sales of $5.7 million for Q4 2025, up from $4.5 million in Q4 2024, indicating stable demand [17] Market Data and Key Metrics Changes - The company consolidated its retail footprint to 23 locations as of December 31, 2025, with plans to further reduce to approximately 19 locations [5][59] - The company is shifting focus from retail to B2B distribution, indicating a strategic pivot in its market approach [59] Company Strategy and Development Direction - The company aims to reach approximately break-even adjusted EBITDA for the full year 2026, focusing on revenue quality rather than volume [14][24] - Plans to increase proprietary brand sales to 40% of cultivation and gardening revenue by year-end 2026 [9][24] - The company is expanding into new revenue channels and product extensions, particularly in B2B and home gardening markets [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term strategy and the potential for sustainable growth in the controlled environment agricultural industry [15][26] - The restructuring efforts have stabilized revenue and improved margins, positioning the company for future profitability [27][28] - Management acknowledged ongoing challenges in the hydroponics market but remains optimistic about the company's ability to adapt and grow [46][52] Other Important Information - The company announced a share repurchase program for up to $10 million of its outstanding common stock, reflecting confidence in its long-term value [14][23] - The company ended 2025 with $46 million in cash and no debt, providing financial flexibility for strategic initiatives [23] Q&A Session Summary Question: Share repurchase program considerations - Management indicated that the decision to repurchase shares was based on the current undervaluation of the stock and the lack of suitable acquisition opportunities [31][32] Question: Sales channels for proprietary brands - Approximately 80% of proprietary brand sales are currently through the company's own channels, with a goal to diversify towards third-party channels [34][35] Question: Outlook for storage solutions segment - Management noted that efforts are being made to consolidate and improve the storage solutions business, which is expected to grow steadily [39][40] Question: Future of retail store closures - The company plans to continue reducing its retail footprint, focusing on B2B operations rather than consumer retail [58][59] Question: Operating expenses and cost reductions - Management expects continued improvements in operating expenses due to prior store closures and ongoing cost reduction initiatives [61]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue reached $5.5 million for the full year, a 97% increase compared to 2024, primarily driven by Truvaga sales [15][16] - Truvaga sales increased by 93% from 2024, totaling $5.4 million [16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - NHS England remains a key channel for international sales, with ongoing efforts to develop infrastructure for reimbursement in other countries [38] Company Strategy and Development Direction - The company is focused on increasing sales within the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as Interim President and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] - The company aims to introduce additional wellness offerings and a next-generation mobile application to support recurring revenue opportunities [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation [12][23] - The leadership transition is seen as an opportunity to maintain operational momentum while focusing on growth strategies [6][7] - The company expects 2026 revenue to continue growing at approximately 30% [23] Other Important Information - Gross margin improved to 87% compared to 85% in 2024 [18] - Research and development expenses increased to $2.7 million, primarily for gammaCore Emerald and mobile application development [19] Q&A Session Summary Question: Can you discuss the channels for gammaCore and Quell in 2026? - Management highlighted the growth in the VA channel and the addition of commercial leaders to accelerate growth [30][31] Question: What about the OUS channels and specific geographies? - NHS England remains the primary focus for international revenue, with ongoing efforts to develop reimbursement pathways in other countries [35][38] Question: Will Michael Fox focus on the VA business while Joshua handles wellness? - Michael will oversee broader commercial strategies, including VA and other federal systems, while Joshua will manage wellness products [44][45] Question: Any updates on insurance reimbursement coverage? - The company is focused on Kaiser as a key opportunity for broader reimbursement adoption, with plans to leverage success for additional managed care systems [58][59]